Introduction
============

Lung cancer has been widely acknowledged to have the highest mortality of all cancer types worldwide, and is classified pathologically as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) ([@b1-mmr-22-04-2916]). Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are identified as the most common subtypes of NSCLC ([@b2-mmr-22-04-2916]). Surgery is the most general treatment for early-stage NSCLC, and the combination of cytotoxic and platinum drugs has become the standard for NSCLC chemotherapy ([@b3-mmr-22-04-2916]). However, the long-term survival for postoperative patients with NSCLC remains poor. Previous studies have indicated that the five-year survival rates of patients with NSCLC with stage Ia, Ib, IIa and IIb are 70, 60, 55 and 40%, respectively ([@b4-mmr-22-04-2916],[@b5-mmr-22-04-2916]). Postoperative adjuvant chemotherapy has a limited effect on improving the survival rate of patients with NSCLC ([@b6-mmr-22-04-2916]). The biomarker cluster of differentiation 24, has been recently identified for use in the prediction of NSCLC disease-free survival ([@b7-mmr-22-04-2916]). However, there are other promising biomarkers with confirmed prognostic value in NSCLC, including matrix metallopeptidase 9, aurora kinase A and enhancer of zeste 2 polycomb repressive complex 2 subunit ([@b8-mmr-22-04-2916]).

Non-SMC condensin I complex subunit H (NCAPH) is a member of the condensin I complex, which is a recently identified superfamily of proteins termed kleisins ([@b9-mmr-22-04-2916]). Condensin I complex consists of three non-SMC subunits; NCAPH, chromosome-associated protein (CAP)D2 and CAPG ([@b10-mmr-22-04-2916]). Condensin serves an indispensable role in chromosome-wide gene regulation and therefore controls the architecture and segregation of sister chromatids ([@b11-mmr-22-04-2916]). In the presence of type I topoisomerase, the condensin complex may introduce positive supercoils into relaxed DNA, while type II topoisomerase is involved in nicked DNA transformation into a positive knotted form ([@b12-mmr-22-04-2916]). Biallelic mutations in CAPD2, NCAPH or CAPD3 are essential to ensure accurate mitotic chromosome condensation in neuron stem cells, ultimately affecting neuron pool and cortex size ([@b13-mmr-22-04-2916]). The authors of the present study previously demonstrated that NCAPH is highly expressed in colon cancer, the knockdown of which inhibits cell proliferation, migration, and xenograft tumor formation abilities ([@b14-mmr-22-04-2916]). However, patients with colon cancer and the overexpression of NCAPH have a markedly improved prognosis compared with patients who demonstrate low-expression of NCAPH ([@b14-mmr-22-04-2916]). Other studies note that highly expressed condensin I complex in non-SMC is associated with the progression of multiple human cancers: Ryu *et al* ([@b15-mmr-22-04-2916]) demonstrated that NCAPH is expressed at a higher level in metastatic melanoma cell lines compared with less aggressive primary tumor cell lines. Other studies have revealed that NCAPH can serve as a potential prognostic indicator for hepatocellular carcinoma and nasopharyngeal cancer ([@b16-mmr-22-04-2916]).

A number of antigens, including carbohydrate antigen 125, are commonly used clinically as auxiliary indicators for the diagnosis of lung cancer, but they exhibit low sensitivity ([@b17-mmr-22-04-2916]). Myeloid cell leukemia sequence 1 (Mcl-1), which is a member of the Bcl-2 family, was originally considered to be an effective short-term promoter for cell survival during the differentiation of bone marrow cells ([@b18-mmr-22-04-2916]--[@b21-mmr-22-04-2916]). Studies have demonstrated that Mcl-1 is a pro-survival protein that is overexpressed in human malignant tumors ([@b22-mmr-22-04-2916],[@b23-mmr-22-04-2916]). Mcl-1, which is involved in chemotherapy resistance and metastasis, is often highly expressed in NSCLC and its association with other markers can improve diagnostic sensitivity ([@b24-mmr-22-04-2916]). The intrinsic apoptotic signaling pathway is closely associated with NCAPH (GO:0097193: <http://www.coexpedia.org/>) ([@b25-mmr-22-04-2916]). The dual expression of NCAPH and Mcl-1 proteins, and their association with clinical and pathological features in NSCLC remain unknown, with the exception of the aforementioned studies.

In the present study, the expression of NCAPH and Mcl-1 was determined in 260 cases of NSCLC, and the association of NCAPH and Mcl-1 expression with clinical and pathological characteristics of NSCLC, and its prognosis, was discussed.

Materials and methods
=====================

### Clinical data

Paraffin-embedded NSCLC tissues from 260 patients diagnosed with primary NSCLC, none of whom had received any treatment before the surgery. All patients had complete clinical and follow-up data. (194 males and 66 females, mean age 60.1±12.76), and 52 control non-cancerous lung disease sections (37 males and 15 females, mean age 57.45±14.56), including bronchiectasis and pneumatocele, were collected from the Second Xiangya Hospital between January 2010 and December 2016. The present study was approved by the Scientific and Research Ethics Committee of the Second Xiangya Hospital (approval no. S039/2011). Patients were fully informed about specimen usage and data retrieval prior to the acquisition of specimens. No information or images that may expose any relevant patient identification or violate any individual rights are presented in the present study. Written informed consent was obtained from each patient. Informed consent was obtained from a parent and/or legal guardian for subjects \<18 years old. All patients with NSCLC underwent surgery and none received neoadjuvant radiotherapy or chemotherapy. Histological diagnosis ([@b26-mmr-22-04-2916]) and staging ([@b27-mmr-22-04-2916]) were performed for all patients to confirm NSCLC. Tissue microarray technology was performed as previously described ([@b28-mmr-22-04-2916],[@b29-mmr-22-04-2916]).

### Immunohistochemistry (IHC) staining and scores

IHC was performed to detect the expression and cellular location of NCAPH and Mcl-1. IHC assay was performed as previously described ([@b16-mmr-22-04-2916],[@b28-mmr-22-04-2916]). Tissues were fixed in paraformaldehyde dehydrated in a graded alcohol series, embedded in paraffin and sectioned at 3 µm. Sections were then deparaffinized, rehydrated and endogenous peroxidase inactivated using methanol containing 0.3% H~2~O~2~. The slides were incubated with appropriate pre-immune serum (Normal Goat Serum, Beyotime Institute of Biotechnology, cat. no. C0269; diluted to 10% in PBS+0.1% Tween20) for 30 min at room temperature to eliminate nonspecific staining, and the sections were stained overnight at 4°C with 1:100 dilution of primary antibody to NCAPH (Rabbit-anti-NCAPH antibody, Fine Test; Wuhan Fine Biotech Co., Ltd., cat. no. FNab05579), recombinant anti-Mcl-1 antibody (Abcam, cat. no. ab32087). Slides were then exposed to an appropriate secondary antibody (MaxvisionTM2 HRP-Polymer anti-Mouse/Rabbit IHC kit, Fuzhou Maixin Biotech. Co., Ltd., dilution: 1:1, cat. no. KIT-5020) for 30 min at 37°C via EnVision^™^+ Dual Link System-HRP (Dako; Agilent Technologies, Inc.). DAB and chromogen solution were used for color reaction enhancement. Hematoxylin was used to counterstain the slides (37°C for 7 min). A light microscope (BX53, Olympus Corporation) was used to visualize slides and the magnification was ×40 (right corner, zoom out) and ×200, respectively.

NCAPH and Mcl-1 protein expression analysis was performed using semi-quantitative evaluation ([@b28-mmr-22-04-2916]). The staining intensity for NCAPH and Mcl-1 was classified on a scale 0--3 based on the observed color intensity (0=negative, no staining; 1=weak, light brown; 2=moderate, brown and 3=strong, dark brown), and positive rates were evenly divided into five grades \[0 (0%), 1 (1--25%), 2 (26--50%), 3 (51--75%), and 4 (76--100%)\]. The final staining score for NCAPH and Mcl-1 was determined by the formula: Staining score=positive rates\* intensity. The best cut-off score for NCAPH was determined as 4 (high expression was determined when the score was ≥4, while scores \<4 were considered negative) based on the survival rate. The optimal cut-off score was determined to be 6 for Mcl-1. The consistency of the two evaluators (Qiuxia Xiong and Songqing Fan) was 95% and differences were solved by discussion between Qiuxia Xiong and Songqing Fan under a two-headed microscope. A light microscope (BX53; Olympus Corporation) was used to visualize slides and the magnification was ×40 (right corner, zoom out) and ×200, respectively.

### Statistical analysis

SPSS version 20.0 was used for statistical analysis (IBM Corp.). The association of NCAPH, Mcl-1, and clinical and pathological characteristics was analyzed via the χ^2^ test and verified using The Cancer Genome Atlas (TCGA) database (v21.0; <http://portal.gdc.cancer.gov/>). The data were generated from the database starBase (v2.0; <http://starbase.sysu.edu.cn/panGeneCoExp.php>). Overall survival curves were obtained using Kaplan-Meier analysis. The Cox proportional hazard regression model was used for multivariate analysis to determine the potential of positive expression of NCAPH and Mcl-1 as poor prognostic indicators. One-way ANOVA was used for comparisons between groups, and t-test was used for further paired comparisons if differences existed. P*\<*0.05 was considered to indicate a statistically significant difference.

Results
=======

### Protein expression of NCAPH and Mcl-1 in the tissues of LUSC and LUAD

The mutation patterns of NCAPH and Mcl-1 in various cancers were examined ([Fig. 1](#f1-mmr-22-04-2916){ref-type="fig"}; [Table I](#tI-mmr-22-04-2916){ref-type="table"}) ([@b30-mmr-22-04-2916]--[@b37-mmr-22-04-2916]). The result showed that the mutation patterns of NCAPH and Mcl-1 existed in various cancers including stomach adenocarcinoma, non-small cell lung cancer, esophagogastric carcinoma, endometrial cancer, colorectal cancer and breast cancer. Immunohistochemistry was conducted to detect the expression and cellular location of NCAPH and Mcl-1 in LUSC, LUAD and the non-cancerous lung control tissues to investigate the connection of NCAPH and Mcl-1 in malignant tissues. The clinicopathological characteristics are presented in [Table II](#tII-mmr-22-04-2916){ref-type="table"}. Expression of NCAPH and Mcl-1 was high in NSCLC tissues and was identified in the cell cytoplasm and nuclear tissues and weak positive expression in the bronchial epithelial cells of non-cancerous normal control lung tissue. In the LUAD and LUSC tissues, Mcl-1 was negatively expressed in the matched tissue in which NCAPH was positively expressed and vice versa ([Fig. 2A-H](#f2-mmr-22-04-2916){ref-type="fig"}). A weak positive expression of NCAPH was identified in the control tissues ([Fig. 2I](#f2-mmr-22-04-2916){ref-type="fig"}). No positive NCAPH staining was observed in the LUAD tissue sections when the matched immunoglobulin G isotype antibody was stained as a negative control ([Fig. 2J](#f2-mmr-22-04-2916){ref-type="fig"}). Weak positive expression of Mcl-1 was revealed in the bronchial epithelial cells of non-cancerous control normal lung tissue ([Fig. 2K](#f2-mmr-22-04-2916){ref-type="fig"}). The negative control demonstrated no expression of Mcl-1 in LUSC ([Fig. 2L](#f2-mmr-22-04-2916){ref-type="fig"}).

The expression of NCAPH and Mcl-1 in the non-cancerous control lung and NSCLC tissues was quantified ([Fig. 2M](#f2-mmr-22-04-2916){ref-type="fig"}); the positive percentage of NCAPH in the non-cancerous lung tissues (84.61%: 44/52) was higher than that in NSCLC (67.69%; 176/260; P=0.015). The positive percentage of Mcl-1 in the non-cancerous lung tissues (15.38%; 8/52) was lower compared with that in NSCLC (81.54%; 212/260; P*\<*0.001). The aforementioned results indicated that the positive expression percentage of NCAPH was lower in tissues harvested from patients with patients while the positive percentages of Mcl-1 were significantly higher compared with control lung tissue sections.

### Association between NCAPH and Mcl-1 and the clinical characteristics in NSCLC

The univariate χ^2^ test was used to examine the influence of the altered expression of NCAPH and Mcl-1 in NSCLC tissues on clinical outcomes. The clinicopathological features investigated included age, clinical stage, sex, lymph node (LNM) status, pathological grade and survival state. The high percentage of Mcl-1 expression was significantly associated with histological type (P*\<*0.0001; [Table III](#tIII-mmr-22-04-2916){ref-type="table"}). The positive percentages of NCAPH were significantly increased in the living group (73.8 vs. 58.0%; P=0.008), while the high percentage of Mcl-1 expression was significantly higher in the mortality group (88.0 vs. 77.5%; P=0.034). However, no association was observed between the expression of NCAPH/Mcl-1 and sex, age, LNM stage or pathological grade.

### The pairwise association between NCAPH and Mcl-1 proteins in NSCLC

Pairwise association ([Table IV](#tIV-mmr-22-04-2916){ref-type="table"}) demonstrated that positive expression of NCAPH protein was associated with negative expression of Mcl-1 protein (r=−0.185, P=0.003), while the positive expression of Mcl-1 protein was associated with negative expression of NCAPH protein (r=−0.185, P=0.003). Therefore, the overexpression of NCAPH protein was negatively associated with the expression of Mcl-1. To evaluate the expression profiles of NCAPH and Mcl-1 in LUAD and LUSC, The Cancer Genome Atlas (TCGA) database was analyzed. The results showed that NCAPH is highly expressed in LUAD and LUSC ([Fig. 3A](#f3-mmr-22-04-2916){ref-type="fig"}), and Mcl-1 is highly expressed in LUAD and LUSC ([Fig. 3B](#f3-mmr-22-04-2916){ref-type="fig"}). In addition, NCAPH expression is negative associated with Mcl-1, as validated in LUAD and LUSC by utilizing the TCGA dataset ([Fig. 3C](#f3-mmr-22-04-2916){ref-type="fig"}) ([@b38-mmr-22-04-2916]). In addition, NCAPH was revealed to be negatively associated with pro-survival members including Bcl-2 and Bcl-w, while being positively associated with pro-apoptotic members Bax and Bid ([Fig. 4A-D](#f4-mmr-22-04-2916){ref-type="fig"}).

### Impact of NCAPH and Mcl-1 expression levels on the prognosis in NSCLC

To serve as a control, no significant difference was detected in the overall survival (OS) between patients with LUAD and LUSC from tissue microarrays used in the current study ([Fig. 5A](#f5-mmr-22-04-2916){ref-type="fig"}; P=0.554). The results of Kaplan-Meier curves indicated that the overall survival rates for patients with lymph node metastasis were lower than for metastasis-free patients (P=0.002; [Fig. 5B](#f5-mmr-22-04-2916){ref-type="fig"}). Meanwhile, higher NCAPH expression in NSCLC was associated with higher OS rates (P=0.003; [Fig. 5C](#f5-mmr-22-04-2916){ref-type="fig"}), while patients with high Mcl-1 expression in NSCLC exhibited significantly worse OS rates (P=0.032; [Fig. 5D](#f5-mmr-22-04-2916){ref-type="fig"}).

Multivariate Cox proportional hazard regression analysis was performed on 260 NSCLC cases. Pathological grades (P=0.017) and clinical stages (P=0.003) were revealed to serve as prognostic factors ([Table V](#tV-mmr-22-04-2916){ref-type="table"}). Additionally, the expression of NCAPH (P=0.003) and Mcl-1 (P=0.038) could be considered as distinct prognostic factors in patients with NSCLC. No clinical effect based on age, sex, histological types, LNM, or treatment strategy was detected.

Discussion
==========

NCAPH is one of the members of the barr gene family and is located on chromosome 2q11.2 ([@b39-mmr-22-04-2916]). A previous study has indicated that NCAPH is one of the essential factors for maintaining cell survival and is indispensable in mitotic chromosome cohesion and separation ([@b40-mmr-22-04-2916]). Mcl-1 is homologous to Bcl-2 and possesses an anti-apoptotic effect in regulating cell survival ([@b41-mmr-22-04-2916]). Compared with healthy lungs, the overexpression of Mcl-1 in NSCLC lines is associated with poor patient prognosis. Mcl-1 belongs to the pro-apoptotic Bcl-2 family, maintains its inactive monomeric state and antagonizes the signaling of cellular apoptosis, particularly in Mcl-1-overexpressing NSCLC cell lines ([@b23-mmr-22-04-2916]). In addition, the depletion of Mcl-1 results in increased sensitivity to radiotherapy and chemotherapy in NSCLC cells ([@b42-mmr-22-04-2916]). Huang *et al* ([@b43-mmr-22-04-2916]) revealed that Mcl-1 promotes the migration of lung cancer cells through a mechanism involving Ca^2+^-dependent reactive oxygen species production. Therefore, Mcl-1 has been demonstrated to serve an important role in NSCLC cell survival by limiting apoptotic signaling.

In the present study, the protein expression of NCAPH and Mcl-1 were examined by IHC in tissues of 260 cases of NSCLC. The data demonstrated that NCAPH and Mcl-1 were highly expressed in NSCLC cancerous tissues; with positive expression in the cytoplasm and nucleus and weak positive expression in the bronchial epithelial cells of non-cancerous normal control lung tissue. The expression of NCAPH and Mcl-1 was negatively associated in the matched tissues of LUAD and LUSC. Pairwise association also demonstrated that NCAPH and Mcl-1 overexpression were inversely associated.

Precise biomarkers are essential for providing a reference for NSCLC prognosis in the tumor-node-metastasis staging system; one of the most effective prognostic methods for operable NSCLC ([@b42-mmr-22-04-2916]). Therefore, it is important to identify novel biomarkers that can help to determine the risks of tumor occurrence and progression. According to the association analysis data between NCAPH and Mcl-1, the high expression percentage of Mcl-1 was positively associated with histological type in NSCLC. In addition, the positive percentage expression of NCAPH was significantly elevated in the living group, while the percentage expression of Mcl-1 was increased in the mortality group. Positive NCAPH expression was associated with higher OS rates, whereas, high Mcl-1 expression was inversely associated with OS rates. These results indicated that the expression of NCAPH and Mcl-1 may be associated with the development and progression of NSCLC and can be considered to be independent prognostic factors. Multiple regulatory mechanisms including ubiquitination and subsequent proteasomal degradation have been shown to control Mcl-1 functions by regulating its expression in response to different stimuli ([@b44-mmr-22-04-2916]). Recent studies validate the non-apoptotic functions of Mcl-1 in autophagy, mitochondrial homeostasis and protein kinase cascade signaling ([@b45-mmr-22-04-2916]). Mcl-1 physically interacts with a number of cell cycle regulators in the nucleus (including PCNA and Chk1), thus regulating the checkpoint response ([@b46-mmr-22-04-2916],[@b47-mmr-22-04-2916]). This leads to the hypothesis that NCAPH could also form a complex with, and negatively regulate, Mcl-1 expression during NSCLC progression. This hypothesis should be investigated in future studies due to the lack of current proteasome data from the NCAPH complex. In conclusion, the expression of NCAPH protein was associated with the expression of Mcl-1 in patients with NSCLC, and the positive expression of NCAPH may serve as one of the independent prognostic factors in surgically resected patients with this disease.
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![The mutation patterns of (A) Mcl-1 and (B) NCAPH in various types of cancer. NCAPH, Non-SMC condensin I complex subunit H; Mcl-1, myeloid cell leukemia sequence 1; STAD, stomach adenocarcinoma; NSCLC, non-small cell lung cancer; ESCA, esophagogastric carcinoma; UCEC, endometrial cancer; COAD, colorectal cancer; BRCA, breast cancer.](MMR-22-04-2916-g00){#f1-mmr-22-04-2916}

![Expression of NCAPH and Mcl-1 proteins in LUAD, LUSC and non-cancerous lung tissues as detected by immunohistochemistry (DAB staining; magnification, ×200. The right corner image is a zoomed-out image with magnification, ×40). (A) NCAPH and (B) Mcl-1 expression in the matched LUAD tissue. (C) Mcl-1 and (D) NCAPH expression in the matched LUAD tissue. (E) NCAPH and (F) Mcl-1 expression in the matched LUSC tissue. (G) Mcl-1 and (H) NCAPH expression in the matched LUSC tissue. (I) The weak positive NCAPH staining in the NCLT. (J) Negative NCAPH expression in the LUAD tissue. (K) The weak positive Mcl-1 staining in the NCLT. (L) Negative Mcl-1 expression in the LUSC tissue. (M) The percentage of positive expression of NCAPH and Mcl-1 proteins in NSCLC tissues was compared to NCLT. \*P\<0.05; \*\*\*P\<0.001; t-test. NCAPH, Non-SMC condensin I complex subunit H; Mcl-1, myeloid cell leukemia sequence 1; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NCLT, non-cancerous lung tissue.](MMR-22-04-2916-g01){#f2-mmr-22-04-2916}

![Elevated expression of NCAPH and Mcl-1 in NSCLC. Significant differential expression of (A) NCAPH and (B) Mcl-1 between tumor and normal tissues in LUAD and LUSC from The Cancer Genome Atlas data. (C) NCAPH association with Mcl-1 in LUAD and LUSC tissues. Data were generated from <http://starbase.sysu.edu.cn/panGeneCoExp.php>. \*\*\*P\<0.001; t-test. NCAPH, non-SMC condensin I complex subunit H; Mcl-1, myeloid cell leukemia sequence 1; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](MMR-22-04-2916-g02){#f3-mmr-22-04-2916}

![The associations between NCAPH and other Bcl-2 members. NCAPH negatively associates with (A) Bcl-2 and (B) Bcl-w in LUAD. NCAPH positively associates with (C) Bax and (D) Bid in LUAD, and P-values are indicated in each figure. NCAPH, non-SMC condensin I complex subunit H; LUAD, lung adenocarcinoma; Bid, BH3 interacting-domain death agonist.](MMR-22-04-2916-g03){#f4-mmr-22-04-2916}

![Kaplan-Meier curves were used to compare the overall survival curves of patients with NSCLC according to clinicopathological characteristics and expression of NCAPH and Mcl-1 proteins. (A) Kaplan-Meier analysis of the patients with LUAD (green) and LUSC (blue) from tissue microarrays used in the current study, P=0.554. (B) Kaplan-Meier analysis of the patients with lymph node metastasis (green) and no lymph node metastasis (blue) from tissue microarrays used in the current study, P=0.002. (C) Kaplan-Meier analysis of the association between NCAPH expression and the overall survival (blue, negative expression of NCAPH; green, positive expression of NCAPH), P=0.003. (D) Kaplan-Meier analysis of the association between Mcl-1 expression and the overall survival (blue, low expression of Mcl-1; green, high expression of Mcl-1), P=0.032. NSCLC, non-small cell lung cancer; NCAPH, non-SMC condensin I complex subunit H; Mcl-1, myeloid cell leukemia sequence 1; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; LNM, lymph node metastasis; SCC, lung squamous carcinoma; ADC, lung adenocarcinoma.](MMR-22-04-2916-g04){#f5-mmr-22-04-2916}

###### 

Data sources of the mutation patterns of NCAPH and Mcl-1 in various types of cancer.

  Author, year                Cancer type                  (Refs.)
  --------------------------- ---------------------------- -------------------------
  Taylor *et al* (2018)       Stomach adenocarcinoma       ([@b30-mmr-22-04-2916])
  Jordan *et al* (2017)       Non-small cell lung cancer   ([@b31-mmr-22-04-2916])
  Janjigian *et al* (2018)    Esophagogastric carcinoma    ([@b32-mmr-22-04-2916])
  Soumerai *et al* (2018)     Endometrial cancer           ([@b33-mmr-22-04-2916])
  Witkiewicz *et al* (2015)   Pancreatic cancer            ([@b34-mmr-22-04-2916])
  Ghandi *et al* (2019)       Cancer of unknown primary    ([@b35-mmr-22-04-2916])
  Yaeger *et al* (2018)       Colorectal cancer            ([@b36-mmr-22-04-2916])
  Pereira *et al* (2016)      Breast cancer                ([@b37-mmr-22-04-2916])

NCAPH, non-SMC condensin I complex subunit H; Mcl-1, myeloid cell leukemia sequence 1.

###### 

Summary of patients with NSCLC and non-cancerous control lung tissues in the tissue arrays.

  A, NSCLC                            
  ----------------------------------- -------------------------
  Age (years)                         
    \<55                              118 (45.4)
    ≥55                               142 (54.6)
  Sex                                 
    Male                              194 (74.6)
    Female                            66 (25.4)
  Clinical stage                      
    Stage I and II                    125 (48.1)
    Stage III and IV                  125 (51.9)
  Lymph node status                   
    No LNM                            111 (42.7)
    LNM                               149 (57.3)
  Histological type                   
    SCC                               129 (49.6)
    ADC                               131 (50.4)
  Differentiation                     
    Well and moderate                 117 (45.0)
    Poor                              143 (55.0)
  Survival state                      
    Living                            160 (61.5)
    Mortality                         100 (38.5)
                                      
  **B, Non-cancerous lung tissues**   
                                      
  **Patients characteristics**        **No. of patients (%)**
                                      
  Age (years)                         
    \<55                              25 (48.1)
    ≥55                               27 (51.9)
  Sex                                 
    Male                              37 (71.2)
    Female                            15 (28.8)

NSCLC, non-small cell lung cancer; LNM, lymph node metastasis.

###### 

Analysis of the association between expression of NCAPH and Mcl-1 proteins and clinicopathological characteristics of NSCLC.

                        NCAPH        Mcl-1                                                                                         
  --------------------- ------------ ----------- ------------------------------------------------------- ------------- ----------- -------------------------------------------------------
  Age (years)                                    0.302                                                                             0.567
    \<55                76 (64.4)    42 (35.6)                                                           98 (83.1)     20 (16.9)   
    ≥55                 100 (70.4)   42 (29.6)                                                           114 (80.3)    28 (19.7)   
  Sex                                            0.922                                                                             0.301
    Male                131 (67.5)   64 (32.5)                                                           161 (83.0)    33 (17.0)   
    Female              45 (68.2)    21 (31.8)                                                           51 (77.3)     15 (22.7)   
  Histological type                              0.858                                                                             \<0.001
    ADC                 88 (68.2)    41 (31.8)                                                           118 (91.51)   11 (8.5)    
    SCC                 88 (67.2)    43 (32.8)                                                           94 (71.8)     37 (28.2)   
  Clinical stages                                0.369                                                                             0.768
    Stage I and II      88 (70.4)    37 (29.6)                                                           101 (80.8)    24 (19.2)   
    Stage III and V     88 (65.2)    47 (34.8)                                                           111 (82.2)    24 (17.8)   
  LNM status                                     0.618                                                                             0.421
    No LNM              77 (69.4)    34 (39.6)                                                           93 (83.8)     18 (16.2)   
    LNM                 99 (66.4)    50 (33.4)                                                           119 (79.9)    30 (20.1)   
  Pathological grade                             0.201                                                                             0.247
    Well and moderate   84 (71.8)    33 (28.2)                                                           99 (84.6)     18 (15.4)   
    Poor                92 (64.3)    51 (35.7)                                                           113 (79.0)    30 (21.0)   
  Survival status                                0.008^[a](#tfn3-mmr-22-04-2916){ref-type="table-fn"}^                             0.034^[a](#tfn3-mmr-22-04-2916){ref-type="table-fn"}^
    Alive               118 (73.8)   42 (26.2)                                                           124 (77.5)    36 (22.5)   
    Succumbed           58 (58.0)    42 (42.0)                                                           88 (88.0)     12 (12.0)   

P\<0.05. Statistical analysis was performed using the χ^2^ test. NCAPH, non-SMC condensin I complex subunit H; Mcl-1, myeloid cell leukemia sequence 1; NSCLC, non-small cell lung cancer; ADC, lung adenocarcinoma; SCC, lung squamous carcinoma; LNM, Lymph node metastasis.

###### 

The pairwise correlation between expression of NCAPH and Mcl-1 proteins in 260 cases of NSCLC.

  Protein                                NCAPH                                                     Mcl-1
  -------------------------------------- --------------------------------------------------------- ---------------------------------------------------------
  NCAPH                                                                                            
    Spearman\'s correlation coincident   1                                                         −0.185
    Significance (2-tailed)              --                                                          0.003^[a](#tfn4-mmr-22-04-2916){ref-type="table-fn"}^
  Mcl-1                                                                                            
    Spearman\'s correlation coincident   −0.185                                                    1
    Significance (2-tailed)                0.003^[a](#tfn4-mmr-22-04-2916){ref-type="table-fn"}^   --

P\<0.05. NCAPH, non-SMC condensin I complex subunit H; Mcl-1, myeloid cell leukemia sequence 1; NSCLC, non-small cell lung cancer; (−), not available.

###### 

Summary of multivariate analysis of Cox proportional hazard regression for overall survival in 260 cases of patients with NSCLC.

                                                                                                95.0% CI for Exp (B)   
  --------------------- ------- ------------------------------------------------------- ------- ---------------------- -------
  Age                   0.001   0.976                                                   1.006   0.667                  1.517
  Sex                   2.442   0.118                                                   0.673   0.409                  1.106
  Histological types    3.285   0.070                                                   1.516   0.967                  2.376
  Pathological grades   5.746   0.017^[a](#tfn6-mmr-22-04-2916){ref-type="table-fn"}^   1.689   1.100                  2.593
  LNM                   3.819   0.051                                                   1.595   0.999                  2.547
  Clinical stages       8.982   0.003^[a](#tfn6-mmr-22-04-2916){ref-type="table-fn"}^   2.055   1.283                  3.291
  Treatment strategy    0.087   0.768                                                   0.918   0.519                  1.624
  NCAPH                 8.539   0.003^[a](#tfn6-mmr-22-04-2916){ref-type="table-fn"}^   0.544   0.361                  0.818
  Mcl-1                 4.324   0.038^[a](#tfn6-mmr-22-04-2916){ref-type="table-fn"}^   1.955   1.039                  3.678

Multivariate analysis of Cox regression

P*\<*0.05. NSCLC, non-small cell lung cancer; LNM, lymph node metastasis; CI, confidence interval; NCAPH, non-SMC condensin I complex subunit H; Mcl-1, myeloid cell leukemia sequence 1.

[^1]: Contributed equally
